QIANG WANG#, GUO ZHAO#, LONGXIANG XIE#, XUAN LI, XIXI YU, QIONGSHAN LI, BAOPING ZHENG, ZULIPINUER WUSIMAN, XIANGQIAN GUO*
BIOCELL, Vol.47, No.2, pp. 367-371, 2023, DOI:10.32604/biocell.2023.025310
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen of the ongoing coronavirus disease 2019 (COVID-19) global pandemic. Here, by centralizing published cell-based experiments, clinical trials, and virtual drug screening data from the NCBI PubMed database, we developed a database of SARS-CoV-2 inhibitors for COVID-19, dbSCI, which includes 234 SARS-CoV-2 inhibitors collected from publications based on cell-based experiments, 81 drugs of COVID-19 in clinical trials and 1305 potential SARS-CoV-2 inhibitors from bioinformatics analyses. dbSCI provides four major functions: (1) search the drug target or its inhibitor for SARS-CoV-2, (2) browse target/inhibitor information collected from cell experiments, clinical trials, and… More >